Biocon’s arm, Just - Evotec Biologics sign licensing deal for biosimilar asset

11 Oct 2019 Evaluate

Biocon’s wholly owned subsidiary -- Biocon Biologics and Just - Evotec Biologics, wholly owned by Evotec, have entered into a strategic licensing agreement for an early-stage, pre-clinical bio-similar asset.

Biocon Biologics will take this bio-similar asset through end-to-end development, IND filing, manufacturing and commercialization post-regulatory approval, under its own label in global markets. Biocon Biologics aims to address the needs of a large patient pool through this differentiated therapy. Through this in-licensing deal, Biocon Biologics has expanded its current therapeutic basket of biosimilars going beyond diabetes, oncology and immunology.

Biocon is India’s largest and Asia’s leading Biotechnology Company with a strategic focus on biopharmaceuticals and research services. It is a fully integrated, innovation-driven biopharma enterprise offering affordable solutions for chronic diseases to patient's worldwide.

Biocon Share Price

385.10 -7.70 (-1.96%)
08-Dec-2025 12:58 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1798.75
Dr. Reddys Lab 1269.90
Cipla 1508.15
Zydus Lifesciences 926.00
Lupin 2070.00
View more..
Register Now to get our Free Newsletter & much more!

© 2025 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×